Drug intelligence / Profile preview

4-(4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol

Development stage: Preclinical
Modality: Small Molecules

Overview

4-(4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol, also known by the code name M77976, is a small molecule that acts as an inhibitor of Pyruvate Dehydrogenase Kinase 4 (PDK4). This compound has been investigated in the context of gastric cancer, where it plays a role in modulating glycolysis. PDK4 inhibition can influence cellular metabolism, particularly in cancer cells, by affecting the Warburg effect.

Targets

PDK (Pyruvate dehydrogenase kinase isoform 1)

Beyond the preview

Go deeper on 4-(4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-(4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol.

Explore the full profile